Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial - 23/12/25
, Nanda Horeweg, MD PhD a, Marie A D Haverkort, MD b, Nienke Kuijsters, MD PhD c, Stefan Kommoss, ProfMD d, Friederike L A Koppe, MD e, Marlies E Nowee, MD PhD f, Henrike Westerveld, MD PhD g, h, Maria A A De Jong, MD i, Filip Frühauf, MD PhD j, Jeltsje S Cnossen, MD PhD k, Jan Willem M Mens, MD h, Jannet C Beukema, MD PhD l, Cyrus Chargari, ProfMD PhD m, Charles Gillham, MD n, Ina M Jurgenliemk-Schulz, MD PhD o, Katrien Vandecasteele, ProfMD PhD p, Moritz Hamann, MD q, Mandy Kiderlen, MD PhD r, Annette Staebler, ProfMD PhD s, Hans W Nijman, ProfMD PhD t, Bastiaan G Wortman, MD PhD a, k, Elefteria Asteinidou, PhD a, Stephanie M de Boer, MD PhD a, Wilbert B van den Hout, PhD v, Karen W Verhoeven-Adema, PhD u, Remi A Nout, ProfMD PhD a, h, Hein Putter, ProfPhD v, Tjalling Bosse, ProfMD PhD w, Carien L Creutzberg, ProfMD PhD aSummary |
Background |
PORTEC-4a investigated molecular risk profile-based individualised adjuvant treatment for women with high-intermediate risk endometrial cancer, aiming to reduce both overtreatment and undertreatment while optimising locoregional control.
Methods |
PORTEC-4a was a randomised, open-label, phase 3, multicentre, non-inferiority trial, conducted across eight European countries. Women (aged ≥18 years and with a WHO performance score of 0–2) with early stage high-intermediate risk endometrial cancer were eligible. Patients were randomly assigned post-surgery in a 2:1 ratio to either adjuvant treatment according to their molecular integrated risk profile or to standard vaginal brachytherapy. Allocation used a biased-coin minimisation with stratification for participating centre, grade, and lymphadenectomy. Adjuvant treatment in the molecular-profile group in case of favourable profile ( POLE -mutated or no specific molecular profile [NSMP]- CTNNB1 wildtype) was observation, for intermediate profile (mismatch repair deficient or NSMP- CTNNB1 mutated) was brachytherapy (21 Gy in three fractions of 7 Gy given at 5 to 7 day intervals), and for unfavourable profile (p53 abnormal or substantial lymphovascular space invasion or L1 cell adhesion molecule overexpression) was pelvic radiotherapy (45·0–48·6 Gy in 1·8–2·0 Gy fractions, 5 days per week). The primary endpoint was overall 5-year cumulative incidence of vaginal recurrence as first event. Kaplan–Meier, Cox model, and cumulative incidence with competing risks were used for final analysis in the intention-to-treat population. Patient advocates were involved during grant application and trial conduct. The trial is registered with the Netherlands Trial Registry (NTR5841), the ISRCTN registry (ISRCTN11659025), and ClinicalTrials.gov ( NCT03469674 ), and follow-up is ongoing.
Findings |
Between June 1, 2016, and Dec 24, 2021, 569 patients were enrolled in PORTEC-4a. After the addition of 23 favourable patients out of PORTEC-4, the final combined PORTEC-4a cohort consisted of 564 eligible and evaluable patients (367 in the molecular profile group and 197 in the standard group). All patients were female, the median age was 69·0 years (IQR 63·0–73·5), and data on race and ethnicity were not collected. Median follow-up was 58·1 months (IQR 40·7–63·6). In the molecular profile group 168 (46%) patients had a favourable profile, 148 (40%) had an intermediate profile, and 51 (14%) had an unfavourable profile. The 5-year cumulative incidence of vaginal recurrence was 4·5% (95% CI 2·23–6·76) in the molecular profile group and 1·6% (0·00–3·32) in the standard group (HR 2·71 [95% CI 0·79–9·34]). The upper-bound of the one-sided confidence interval of the difference (5·3%) was below the predefined-equivalence margin of 7·0% (p non-inferiority =0·005). The second primary analysis in patients with a favourable molecular profile showed 5-year vaginal recurrence of 4·1% (95% CI 0·81–7·37) in the molecular profile group versus 0·9% (0·00–2·78) in the standard group (HR 3·97 [95% CI 0·48–32·95]). Adverse events were mainly grades 1–2, with grade 3 or above related genitourinary toxicities in four (1%) of 367 versus four (2%) of 197, without substantial differences between groups. Five serious adverse events occurred, of which one was possibly related to treatment (vaginal scar dehiscence). No treatment-related deaths occurred.
Interpretation |
Individualised adjuvant treatment by molecular integrated risk profile is safe and effective for patients with high-intermediate risk endometrial cancer; it spared 46% of patients with a favourable profile from adjuvant treatment, and reduces both overtreatment and undertreatment.
Funding |
KWF Dutch Cancer Society.
Le texte complet de cet article est disponible en PDF.Plan
Vol 27 - N° 1
P. 23-35 - janvier 2026 Retour au numéro
Article précédent
- Current landscape, successes, and key challenges in cancer vaccine clinical trials across the UK
- Robert A Watson, Darcy Ward, Pippa Corrie, Elisa Fontana, William Ince, Victoria Kunene, Siow-Ming Lee, Mark Linch, Nangi Lo, Christian Ottensmeier, Miranda Payne, David Pinato, Thomas Powles, Elizabeth Smyth, Stefan N Symeonides, Fiona Thistlethwaite, Ojas Rajkumar, Henry Li, Lennard Lee
- Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study
- Yi-Long Wu, Yu Yao, Jin-Ji Yang, Lin Wu, Wei Zhang, Ying Wang, Hai-Peng Xu, Yong Song, Yan Zhang, Jun Zhao, Jing-Hua Chen, Zhe-Hai Wang, Qi-Ming Wang, Jie Hu, Xing-Ya Li, Yun Fan, Yuan Chen, Jian Fang, Di Han, Wei-Zhe Xue, Si-yang Maggie Liu, Qing Zhou, Pei-Long Zhang, He-Peng Shi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?